Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;66(3):201-2.
doi: 10.4212/cjhp.v66i3.1261.

Deprescribing: what is it and what does the evidence tell us?

Wade Thompson  1 , Barbara Farrell
Affiliations

Deprescribing: what is it and what does the evidence tell us?

Wade Thompson et al. Can J Hosp Pharm. 2013 May.
No abstract available

PubMed Disclaimer

References

    1. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51. doi: 10.1016/j.amjopharm.2007.12.002. - DOI - PubMed
    1. Ziere G, Dieleman JP, Hofman A, Pols HAP, Van Der Cammen TJ, Stricker BHC. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006;61(2):218–23. doi: 10.1111/j.1365-2125.2005.02543.x. - DOI - PMC - PubMed
    1. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging. 2009;26(12):1039–48. doi: 10.2165/11319530-000000000-00000. - DOI - PubMed
    1. Farrell B, Thompson W. The evidence for deprescribing: trials and tribulations [presentation]. Canadian Society of Hospital Pharmacists Professional Practice Conference; 2013 Feb 3–6; Toronto (ON).
    1. Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237–53. doi: 10.1016/j.cger.2012.01.006. - DOI - PubMed

LinkOut - more resources